
CURRICULUM VITAE ET STUDIORUM

Davide Melisi, MD, PhD

Date of birth: October 29th, 1976

Associate Professor of Medical Oncology

Director of the Digestive Molecular and Clinical Oncology research Unit

University of Verona

Director of the Investigational Cancer Therapeutics Clinical Unit

University Hospital of Verona

AOUI Policlinico "Giambattista Rossi"

Piazzale L.A.Scuro, 10

37134, Verona, Italy

tel.: +39 045 8128148

email: davide.melisi@univr.it

Married, with three children, Lorenzo, Miriam, and Stefano. Davide Melisi is Associate Professor of Medical Oncology at the University of Verona and Director of the Investigational Cancer Therapeutics Unit at the University Hospital of Verona. Prof. Melisi has dedicated his career to oncology research. He's worked on basic, translational, and clinical research, with a focus on gastrointestinal neoplasms, at different previous institutions, including the University of Naples "Federico II," the Department of Gastrointestinal Medical Oncology at the MD Anderson Cancer Center Houston, TX, and the National Cancer Institute in Naples, Italy.

In 2011, he received a prestigious grant from the Italian Association for Cancer Research, establishing the Molecular Clinical Oncology Research Unit for the Digestive System at the University of Verona. This unit primarily researches molecular mechanisms behind resistance to chemotherapy and targeted drugs in gastrointestinal neoplasms.

Professor Melisi has secured substantial research funding, exceeding 10 million euros, for laboratory and clinical research. He actively contributes to the Pancreas Institute, participates in early-phase development of experimental oncology therapies, and teaches medical oncology.

He's received various prestigious awards, such as the "Prof. Piero Trivella" 2003 award, "Marion D. Edwards" 2007 award in hepatic oncology, "Nunzio Pascale" 2008 award, "SS. Cosma e Damiano" 2016 award, and the "Gaetano Salvatore" Award in 2023.

In 2019, he was honored as Knight Officer of the Order of Merit of the Italian Republic by decree of the Italian President Sergio Mattarella for his contributions to patient care, research, and teaching.

In 2020, he received the Italian Certification for tenured Full Professorship of Medical Oncology.

Education and degrees awarded

2001	MD Degree, Summa cum Laude, University of Naples "Federico II" Medical School, Italy
2005	Specialty Degree in Medical Oncology, Summa cum Laude, University of Naples "Federico II", Italy
2009	PhD Degree, International Doctorate Program in Molecular Oncology and Endocrinology, University of Naples "Federico II", Italy

Positions and Employment

2001-2005	Resident/Fellow, Internal Medicine/Medical Oncology, Division of Medical Oncology, University of Naples "Federico II" Medical School, Italy
2005-2009	Postdoctoral Fellow, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center – University of Texas, Houston, TX, US

2009-2011	Clinical and Experimental Tenure Lecturer, National Cancer Institute – Fondazione G. Pascale, Naples, Italy
2011-2018	Assistant Professor, Department of Medicine, University of Verona, Italy
2011-	Head, Digestive Molecular Clinical Oncology Research Unit, University of Verona, Italy
2018-	Associate Professor, Department of Medicine, University of Verona, Italy
2020-	Head, Investigational Cancer Therapeutics Clinical Unit, AOUI Verona
2020 -	Italian Certification for tenured Full Professorship of Medical Oncology

Scientific Awards, Honors, and Fellowships

2003	“Prof. Piero Trivella” award, Italian Cancer Society (SIC), Italy
2005	“Leonino Fontana e Maria Lionello” award, Italian Foundation for Cancer Research (FIRC), Italy
2007	Fellow at the NCI-AACR Cancer Research Imaging Camp, Duke University, Durham, NC, USA
2007	“The Marion D. Edwards” award in Hepatic Oncology, MD Anderson Cancer Center, Houston, TX, US
2008	Fellow at the Methods in Clinical Cancer Research AACR/ASCO Workshop, Vail, CO
2008	“Nunzio Pascale” International award for cancer research – “Nunzio Pascale” Foundation, Italy
2008	The SASS Foundation for Medical Research Postdoctoral Research Fellowship, Roslyn, NY, US
2008	American-Italian Cancer Foundation Postdoctoral Fellowship, New York, NY, US
2019	Honor of Knight Officer of the Order of Merit of the Italian Republic from the Italian President Sergio Mattarella.
2023	“Gaetano Salvatore” award for medical research – Il Cenacolo delle Scienze Foundation

Research Support

AIRC Investigator Grant n. 30711, 2025-2030

Learning through clinical validation to unravel the complexity of TGFβ signaling in current and future PDAC treatments

Role: PI – Budget: 1 427 805 euro

PNRR -M4C2- I1.3 Project PE_00000019 "HEAL ITALIA"., 2023-2025

Clinical validation and implementation of innovative predictive, preventive, diagnostic and therapeutic precision medicine approaches, based on established or emerging molecular and clinical phenotyping and AI-driven decision-making protocols

Role: PI – Budget: 240 000 euro

AIRC Investigator Grant n. 23719, 2020-2025

Mechanistic basis for improving the efficacy of targeting TGFβ pathway in poor prognosis pancreatic cancer patients – Associazione Italiana per la Ricerca sul Cancro

Role: PI – Budget: 826 000 euro

AIRC Special Program Molecular Clinical Oncology 5 per mille Extension Program n. 12182, 2018-2020

Clinically applicable biomarkers to early diagnosis, patient risk stratification and therapy response in pancreas cancer

Role: participating unit – Budget: 120 000 euro

Incyte corporation

A phase II trial of the FGFR inhibitor INCB54828 in patients with HER2-positive advanced EGJ/Gastric cancer Trastuzumab Resistant: the FiGhTeR trial

Role: PI – Budget: 394 740 euro

Shire Baxalta US Inc.

A Phase II Study of Liposomal Irinotecan (nal-IRI) with 5 Fluorouracil, Leucovorin, and Oxaliplatin in Patients With Resectable Pancreatic Cancer: the nITRo trial

Role: PI – Budget: 720 200 euro

AIRC Investigator Grant n. 19111, 2017-2020

Dissecting Smad-dependent and Smad-independent TGF β signaling pathways for the treatment of pancreatic cancer – Associazione Italiana per la Ricerca sul Cancro

Role: PI – Budget: 554 040 euro

Ministero della Salute – Ricerca Finalizzata 2016

A Biomarker-driven Therapeutic Strategy for Esophageal Cancer, the BoRgES trial: a multicenter randomized phase II study of BIRC3-expression directed preoperative chemoradiotherapy in patients with Resectable adenocarcinoma of the Esophagus

Role: PI – Budget: 450 000 euro

Basic Research Project 2015, 2016-2018

Identification of the paracrine molecular networks linking obesity and pancreatic cancer progression University of Verona

Role: PI – Budget: 58 000 euro

AIRC Special Program Molecular Clinical Oncology 5 per mille n. 10016, 2013-2016

Molecular basis for triple negative breast cancer metastasis: new tools for diagnosis and therapy – Associazione Italiana per la Ricerca sul Cancro

Role: participating unit – Budget: 60 000 euro

AIRC Start-Up Grant n. 10129, 2010-2016

Mechanisms of resistance to chemotherapeutic and antiangiogenic drugs as targets for pancreatic cancer therapy – Associazione Italiana per la Ricerca sul Cancro

Role: PI – Budget: 740 000 euro

Selected oral presentations at international and national scientific meetings

ESMO Congress 2024 - Novel targeted therapies for pancreatic cancer, Barcelona, 13-17/09/2024

EASL Liver Cancer Summit 2020 - Oral Presentation, FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA), Prague, 6-8/2/2020

XV National Congress of the Portuguese Digestive Cancer Research Group - Omics and Precision Medicine in gastric cancer – Algarve, Portugal, 10-12/10/19

XII International Gastric Cancer Congress – Prognostic or Predictive Biomarkers for Gastric Cancer – Beijing, China, 20-23/04/2017

2016 ASCO Annual Meeting, Poster Discussion Session – Gastrointestinal (Noncolorectal) Cancer - A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC), Chicago, 03-07/06/2016

AACR 107th Annual Meeting 2016, Proffered Oral Presentation – Early Clinical Trials of Novel Agents - A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC), New Orleans, 16-20/04/2016

53° Congresso Nazionale della Società Italiana di Cancerologia - Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT, Torino, 19-22/10/2011

XII Congresso Nazionale di Oncologia Medica AIOM - Nuove conoscenze bio-molecolari nei tumori del pancreas, Roma, 06-08/11/2010

Oral presentation - ECCO 15 – 34th ESMO Multidisciplinary Congress - TGF- β -activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance, Berlin, 20-24/09/2009

Most relevant clinical trials conducted as Principal Investigator

A **phase 1/randomized phase 2**, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine or gemcitabine+placebo in patients with advanced or metastatic unresectable pancreatic cancer. - Sponsor: Eli Lilly and Company. ClinicalTrials.gov Identifier: NCT01373164

A **phase 1** study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer. Ruolo: Principal Investigator - Sponsor: Eli Lilly and Company. ClinicalTrials.gov Identifier: NCT02734160

Investigator Initiated Trial - A **phase 2** study of Liposomal Irinotecan (nal-IRI) with 5 Fluorouracil, Leucovorin, and Oxaliplatin in Patients With Resectable Pancreatic Cancer: the nITRo trial. Sponsor: Shire Pharmaceutical - Budget: 720 200 euro

Investigator Initiated Trial - A Biomarker-driven Therapeutic Strategy for Esophageal Cancer, the BoRgES trial: a multicenter randomized **phase 2** study of BIRC3-expression directed preoperative chemoradiotherapy in patients with Resectable adenocarcinoma of the Esophagus. Sponsor: Ministero della Salute – Ricerca Finalizzata 2016 - Budget: 450 000 euro

Investigator Initiated Trial - A **phase 2** trial of the FGFR inhibitor INCB54828 in patients with HER2-positive advanced EGJ/Gastric cancer Trastuzumab Resistant: the FiGhTeR trial - Sponsor: Incyte co. - Budget: 394 740 euro

A **phase 1**, Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies - Sponsor: Incyte Corporation - ClinicalTrials.gov Identifier: NCT03144661

A **phase 2**, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy. - Sponsor: Incyte Corporation - ClinicalTrials.gov Identifier: NCT02924376

A phase 3 Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302). - Sponsor: Incyte Corporation - ClinicalTrials.gov Identifier: NCT03656536

A **phase 1** Study of LY3200882 in Participants With Solid Tumors. Sponsor: Eli Lilly and Company. ClinicalTrials.gov Identifier: NCT02937272

A randomized **phase 2** study of second-line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first-line gemcitabine-based chemotherapy - Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Netherlands - ClinicalTrials.gov Identifier: NCT03986294

A **phase 3** trial comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer - Sponsor: NuCana plc - ClinicalTrials.gov Identifier: NCT04163900

Development of the Autotaxin inhibitor IOA-289 in models of pancreatic cancer – Sponsor: iOnctura SA (Geneva, Switzerland)

A **phase 2** trial of Futibatinib in Patients With Specific FGFR Aberrations - Sponsor: Taiho Oncology, Inc. - ClinicalTrials.gov Identifier: NCT04189445

An Open-label, Randomised, Multicentre, **Phase 3** Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas – Sponsor : Ipsen- ClinicalTrials.gov Identifier: NCT04083235

Peer-reviewed publications

1. Tortora G, Caputo R, Damiano V, Fontanini G, **Melisi D**, Veneziani BM, Zunino F, Bianco AR, Ciardiello F. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res. 2001 7(12): 4156-63.
2. Tortora G, Caputo R, Damiano V, **Melisi D**, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003 9(4): 1566-72.
3. Tortora G, **Melisi D** and Ciardiello F. Angiogenesis: A Target for Cancer Therapy. Curr Pharm Des. 2004 10(1): 11-26.
4. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, **Melisi D**, De Vita F, De Placido S, Bianco AR, Tortora G. Antitumor Activity of ZD6474, a VEGFR Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Anti-EGFR Therapy. Clin Cancer Res. 2004 10(2): 784-793.
5. **Melisi D**, Troiani T, Damiano V, Tortora G and Ciardiello F. Therapeutic integration of signal transduction targeting agents and conventional anti- cancer treatments. Endocr Relat Cancer. 2004 11(1): 51-68.
6. Raben D, Bianco C, Damiano V, Bianco R, **Melisi D**, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 3(8): 977-83.
7. Damiano V, **Melisi D**, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 2005 11(15): 5639-44.
8. **Melisi D**, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F and Tortora G. Zoledronic acid cooperates with a COX-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 2005 12(4):1051-8.

9. Bianco R, **Melisi D**, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. *Eur J Cancer*. 2006 42(3):290
10. **Melisi D**, Chiao PJ. NF-kappaB as a target for cancer therapy. *Expert Opin Ther Targets*. 2007 Feb;11(2):133-44.
11. **Melisi D**, Ishiyama S, Scialabba GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a Novel Transforming Growth Factor β Receptor type I and II dual inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis. *Mol Cancer Ther*. 2008 Apr;7(4):829-40.
12. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, **Melisi D**, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. *Clin Cancer Res*. 2008 Aug 15;14(16):5069-80.
13. **Melisi D**, Niu J, Chang Z, Ishiyama S, Peng B, Xia Q, Evans DB, and Chiao PJ. Secreted Interleukin-1 α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of NF- κ B. *Mol Cancer Res*. 2009 May;7(5):624-33.
14. **Melisi D**, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. *Clin Cancer Res*. 2009 Oct 5;15(20):6367-77.
15. **Melisi D**, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ. Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. *J Natl Cancer Inst*. 2011 Aug 3;103(15):1190-204.
16. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao P, Abbruzzese JL, and **Melisi D**. Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete Proinflammatory Factors that Contribute to Malignant Progression by Inducing an EMT cell phenotype. *Clin Cancer Res*. 2011 Sep 1;17(17):5822-32.
17. Vaccaro V*, **Melisi D***, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. *Expert Opin Ther Targets*. 2011 Oct;15(10):1183-96. *CFA
18. Rosa R, **Melisi D**, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-Ras mutant colorectal and pancreatic cancers. *Clin Cancer Res*. 2011 Oct 15;17(20):6531-41.
19. Carbone C, and **Melisi D**. NF-kappaB as a target for pancreatic cancer therapy. *Expert Opin Ther Targets*. *Expert Opin Ther Targets*. 2012 Apr;16 Suppl 2:S1-10.
20. **Melisi D**, Budillon A. Editorial: pancreatic cancer: between bench and bedside. *Curr Drug Targets*. 2012 Jun 1;13(6):729-30.
21. Tamburrino A, Piro G, Carbone C, Tortora G, and **Melisi D**. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. *Front Pharmacol*. 2013 Apr 30;4:56.
22. **Melisi D**, Piro G, Tamburrino A, Carbone C, Tortora G. Rationale and clinical use of multitargeting anticancer agents. *Curr Opin Pharmacol*. 2013 Aug;13(4):536-42.
23. **Melisi D**, Calvetti L, Frizziero M, Tortora G. Pancreatic cancer: systemic combination therapies for a heterogeneous disease. *Curr Pharm Des*. 2014;20(42):6660-9.
24. Lucchini E, Pilotto S, Spada E, **Melisi D**, Bria E, Tortora G. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. *Expert Opin Drug Saf*. 2014 May;13(5):535-49.
25. Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, **Melisi D**, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget*. 2014 May 15;5(9):2839-52.
26. **Melisi D**, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G. Toll-Like Receptor 9 Agonists for Cancer Therapy. *Biomedicines*. 2014 Aug 4;2(3):211-228.

27. Simionato F, Frizziero M, Carbone C, Tortora G, and **Melisi D**. Current strategies to overcome resistance to ALK-inhibitor agents. *Curr Drug Metab*. 2015;16(7):585-96.
28. Dalla Pozza E, Dando I, Biondani G, Brandi J, Costanzo C, Zoratti E, Fassan M, Boschi F, **Melisi D**, Cecconi D, Scupoli MT, Scarpa A, Palmieri M. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. *Int J Oncol*. 2015 Mar;46(3):1099-108.
29. Vaccaro V, Sperduti I, Vari S, Bria E, **Melisi D**, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? *World J Gastroenterol*. 2015 Apr 28;21(16):4788-801.
30. Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanutto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, and **Melisi D**. An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. *Oncotarget*. 2014 Oct 24. pii: 2635.
31. Piro G, Giacomuzzi S, Bencivenga M, Carbone C, Verlato G, Frizziero M, Zanutto M, Mina MM, Merz V, Santoro R, Zaroni A, De Manzoni G, Tortora G, and **Melisi D**. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. *Br J Cancer*. 2015 Sep 15;113(6):878-85.
32. Carbone C, Tamburrino A, Piro G, Boschi F, Cataldo I, Zanutto M, Mina MM, Zanini S, Sbarbati A, Scarpa A, Tortora G, and **Melisi D**. Combined inhibition of IL1, CXCR1/2, and TGF β signaling pathways modulates in vivo resistance to anti-VEGF treatment. *Anticancer Drugs*. 2015 Oct 15
33. Brannon AR, Frizziero M, Chen D, Hummel J, Gallo J, Riester M, Patel P, Cheung W, Morrissey M, Carbone C, Cottini S, Tortora G, and **Melisi D**. Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001. *Cold Spring Harb Mol Case Stud*. 2016 Mar;2(2):a000620.
34. Zhuang Z, Ju H, Aguilar M, Gocho T, Li H, Iida T, Lee H, Fan X, Zhou H, Ling J, Li Z, Fu J, Wu M, Li M, **Melisi D**, Iwakura Y, Xu K, Fleming JB, Chiao PJ. IL-1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF- κ B Activation. *Clin Cancer Res*. 2016 Mar 15;22(6):1432-44.
35. Pietrantonio F, Caporale M, Morano F, Scartozzi M, Ghossein A, De Vita F, Gionmonni E, Fornaro L, Aprile G, **Melisi D**, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864.
36. Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacomuzzi S, Aprile G, Simionato F, Boschi F, Zanutto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, and **Melisi D**. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. *Clin Cancer Res*. 2016 Jun 7.
37. Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, Merz V, Scarpa A, Bassi C, Tortora G, and **Melisi D**. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. *Oncoimmunology*. 2017 Apr 28;6(9):e1322242.
38. Pelzer U, Blanc JF, **Melisi D**, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWIST analysis. *Br J Cancer*. 2017 May 9;116(10):1247-1253.
39. Humphries MP, Sundara Rajan S, Droop A, Suleman C, Carbone C, Nilsson C, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Walker RA, Kulka J, Ellis IO, Jeffery M, Thygesen HH, Cappelletti V, Daidone MG, Hedenfalk IA, Fjällskog ML, **Melisi D**, Stead L, Shaaban A, Speirs V. A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer. *Clin Cancer Res*. 2017 May 15;23(10):2575-2583.
40. Aprile G, Negri FV, Giuliani F, De Carlo E, **Melisi D**, Francesca Simionatoe, Nicola Silvestrisd, Oronzo Brunettid, Francesco Leonef, Donatella Marinof, Daniele Santinig, Emanuela Dell'Aquilag, Tea Zeppola, Marco Puzzone,

Mario Scartozzi. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? *Crit Rev Oncol Hematol*. 2017 Jul;115:1-12.

41. Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Ali G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, and **Melisi D**. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients. *Clin Cancer Res*. 2017 Aug 1;23(15):4312-4322.
42. Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, **Melisi D**, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *Gastric Cancer*. 2017 Sep;20(5):825-833.
43. Gaianigo N, **Melisi D**, Carbone C. EMT and Treatment Resistance in Pancreatic Cancer. *Cancers (Basel)*. 2017 Sep 12;9(9).
44. Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Donato SD, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, **Melisi D**, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Future Oncol*. 2017 Oct;13(25):2265-2275.
45. Federti E, Matte' A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, **Melisi D**, Kim DW, Levi S, De Franceschi L. Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. *Free Radic Biol Med*. 2017 Nov;112:376-386.
46. Federti E, Matte A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, **Melisi D**, Kim DW, Levi S, De Franceschi L. Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. *Data Brief*. 2017 Sep 30;15:376-381
47. Santoro R, Carbone C, Piro G, Chiao PJ, **Melisi D**. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. *Drug Resist Updat*. 2017 Nov;33-35:36-42.
48. Matte A, De Falco L, Federti E, Cozzi A, Iolascon A, Levi S, Mohandas N, Zamo A, Bruno M, Leboeuf C, Janin A, Siciliano A, Ganz T, Federico G, Carlomagno F, Mueller S, Silva I, Carbone C, **Melisi D**, Kim DW, Choi SY, DE Franceschi L. Peroxiredoxin-2: a novel regulator of iron homeostasis in ineffective erythropoiesis. *Antioxid Redox Signal*. 2018 Jan 1;28(1):1-14.
49. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, **Melisi D**, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist*. 2017 Dec;22(12):1463-1469.
50. Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, **Melisi D**. Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. *Int J Mol Sci*. 2018 Feb 1;19(2).
51. Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, **Melisi D**. The development of PARP as a successful target for cancer therapy. *Expert Rev Anticancer Ther*. 2018 Feb;18(2):161-175.
52. Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, **Melisi D**. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. *Int J Obes (Lond)*. 2018 Mar;42(3):334-343.
53. Innamorati G, Wilkie TM, Kantheti HS, Valenti MT, Dalle Carbonare L, Giacomello L, Parenti M, **Melisi D**, Bassi C. The curious case of Gas gain-of-function in neoplasia. *BMC Cancer*. 2018 Mar 15;18(1):293.
54. Piro G, Carbone C, Santoro R, Tortora G, **Melisi D**. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. *Expert Rev Mol Diagn*. 2018 Mar 16.

55. Santoro R, Zanutto M, Carbone C, Piro G, Tortora G, **Melisi D**. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. *Anticancer Res.* 2018 Apr;38(4):1937-1946.
56. Paiella S, Salvia R, De Pastena M, Pollini T, Casetti L, Landoni L, Esposito A, Marchegiani G, Malleo G, De Marchi G, Scarpa A, D'Onofrio M, De Robertis R, Pan TL, Maggino L, Andrianello S, Secchettin E, Bonamini D, **Melisi D**, Tuveri M, Bassi C. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. *Pancreatology.* 2018 Apr 10. pii: S1424-3903(18)30068-1.
57. Trestini I, Carbognin L, Sperduti I, Bonaiuto C, Auriemma A, **Melisi D**, Salvatore L, Bria E, Tortora G. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. *Eur J Clin Nutr.* 2018 May;72(5):772-779.
58. Ciaravino V, Cardobi N, DE Robertis R, Capelli P, **Melisi D**, Simionato F, Marchegiani G, Salvia R, D'Onofrio M. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. *Anticancer Res.* 2018 Aug;38(8):4889-4895. doi: 10.21873/anticancer.12803.
59. **Melisi D**, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Tabernero J. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. *Br J Cancer.* 2018 Oct 15.
60. Cascetta P, Cavaliere A, Piro G, Torroni L, Santoro R, Tortora G, **Melisi D**, Carbone C. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. *Int J Mol Sci.* 2018 Oct 25;19(11).
61. Marchegiani G, Andrianello S, Dal Borgo C, Secchettin E, **Melisi D**, Malleo G, Bassi C, Salvia R. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. *HPB (Oxford).* 2018 Oct 23.
62. Hubner RA, Cubillo A, Blanc JF, **Melisi D**, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. *Eur J Cancer.* 2018 Nov 17;106:24-33.
63. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, **Melisi D**, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biccato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat Commun.* 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.
64. Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, **Melisi D**, Vasile E, Gerrata L, Aprile G. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. *J Geriatr Oncol.* 2018 Dec 11.
65. **Melisi D**, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J. TGF β receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. *Cancer Chemother Pharmacol.* 2019 May;83(5):975-991.
66. Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprari D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, **Melisi D**, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. *JAMA Surg.* 2019 Jul 24. doi: 10.1001/jamasurg.2019.2277.
67. Gueorguieva I, Tabernero J, **Melisi D**, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- β inhibitor galunisertib in patients with pancreatic cancer. *Cancer Chemother Pharmacol.* 2019 Nov;84(5):1003-1015.

68. Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Triscioglio D, Iuliano A, Del Bufalo D, Di Bernardo D, **Melisi D**, Draetta GF, Ciliberto G, Carugo A, Cardone L. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. *Cancer Res.* 2019 Nov 1;79(21):5612-5625.
69. Santoro R, Zanutto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, **Melisi D**. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer. *Mol Cancer Ther.* 2019 Sep 27.
70. Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, **Melisi D**. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. *J Gastric Cancer.* 2019 Dec;19(4):375-392. doi: 10.5230/jgc.2019.19.e39. Epub 2019 Nov 13.
71. Taieb J, Prager GW, **Melisi D**, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. *ESMO Open.* 2020 Jan;5(1).
72. Park SY, Matte A, Jung Y, Ryu J, Wilson AB, Han EYA, Liu M, Carbone C, **Melisi D**, Nagasawa T, Locascio JJ, Lin CP, Silberstein LE, De Franceschi L. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion. *Blood.* 2020 Jan 27. pii: blood.2019002227. doi: 10.1182/blood.2019002227.
73. Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, **Melisi D**, Scarpa A, Ciuffreda L, Milella M, Cognetti F. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells.* 2020 Jan 28;9(2).
74. Caccialanza R, Cereda E, Klersy C, Brugnattelli S, Borioli V, Ferrari A, Caraccia M, Lobascio F, Pagani A, Delfanti S, Aprile G, Reni M, Rimassa L, **Melisi D**, Cascinu S, Battistini L, Candiloro F, Pedrazzoli. Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. *Ther Adv Med Oncol.* 2020 Feb 22;12:1758835919890281.
75. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, **Melisi D**, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol.* 2020 Mar 20. pii: S1470-2045(20)30109-1. doi: 10.1016/S1470-2045(20)30109-1.
76. De Robertis R, Beleù A, Cardobi N, Frigerio I, Ortolani S, Gobbo S, Maris B, **Melisi D**, Montemezzi S, D'Onofrio M. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. *Abdom Radiol (NY).* 2020 Apr 7.
77. Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, **Melisi D**. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. *Cancers (Basel).* 2020 Apr 30;12(5):1131.
78. Trestini I, Paiella S, Sandini M, Sperduti I, Elio G, Pollini T, **Melisi D**, Auriemma A, Soldà C, Bonaiuto C, Tregnago D, Avancini A, Secchettin E, Bonamini D, Lanza M, Pilotto S, Malleo G, Salvia R, Bovo C, Gianotti L, Bassi C, Milella M. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. *Ann Surg Oncol.* 2020 May 9.
79. Fedele V, **Melisi D**. Permissive State of EMT: The Role of Immune Cell Compartment. *Front Oncol.* 2020 Apr 22;10:587.
80. Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, Martini M, Tortora G, Ugel S, Corbo V, **Melisi D**, Carbone C. Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. *Front Cell Dev Biol.* 2020 Apr 28;8:308.
81. Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, and **Melisi D**. Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer. *Clin Cancer Res.* 2020. DOI: 10.1158/1078-0432.CCR-20-0395

82. Zuliani S, Zampiva I, Tregnago D, Casali M, Cavaliere A, Fumagalli A, Merler S, Riva ST, Rossi A, Zacchi F, Zaninotto E, Auriemma A, Pavarana M, Soldà C, Benini L, Borghesani M, Caldart A, Casalino S, Gaule M, Kadrija D, Mongillo M, Pesoni C, Biondani P, Cingarlini S, Fiorio E, **Melisi D**, Parolin V, Tondulli L, Belluomini L, Zecchetto C, Avesani B, Biasi A, Bovo C, Dazzani E, Dodi A, Gelmini S, Leta LC, Lo Cascio G, Lombardo F, Lucin E, Martinelli IA, Messineo L, Moscarda V, Pafumi S, Reni A, Sartori G, Scaglione IM, Shoval Y, Sposito M, Tacconelli E, Trestini I, Zamboni V, Zanelli S, Pilotto S, Milella M. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *Eur J Cancer*. 2020 Jun 11;135:159-169.
83. Bekaii-Saab TS, Valle JW, Cutsem EV, Rimassa L, Furuse J, Ioka T, **Melisi D**, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. *Future Oncol*. 2020 Jul 17.
84. Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacomuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, **and Melisi D**. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. *Ther Adv Med Oncol*. 2020 Jul 7 ;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020.
85. Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuvèri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbriellini A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, **and Melisi D**. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. *Ther Adv Med Oncol*. 2020 Sep 4;12:1758835920947969.
86. Merz V, Zecchetto C, **and Melisi D**. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. *Future Oncol*. 2020 Oct 9.
87. Luchini C, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, **Melisi D**, Salvia R, Malleo G, Shin JI, Cargnin S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *J Exp Clin Cancer Res*. 2020 Oct 28;39(1):227.
88. Contarelli S, Fedele V, **Melisi D**. HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. *Cancers (Basel)*. 2020 Nov 8;12(11):E3299.
89. Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H, Feliz L, Zecchetto C, **Melisi D**, Burn TC. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. *Cancer Discov*. 2020 Nov 20:CD-20-0766.
90. Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquez MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, **Melisi D**, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. *ESMO Open*. 2021 Jan 4;6(1):100032.
91. Carrato A, **Melisi D**, Prager G, Westphalen CB, Ferreras A, D'Esquermes N, Taieb J, Mercadé TM. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. *Future Oncol*. 2021 Mar 5.
92. **Melisi D**, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. *J Immunother Cancer*. 2021 Mar;9(3):e002068.
93. Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, **and Melisi D**. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. *Front Oncol*. 2021 Mar 11;11:638360.

94. **Melisi D**, Cavaliere A, Gobbo S, Fasoli G, Allegrini V, Simionato F, Gaule M, Casalino S, Pesoni C, Zecchetto C, Merz V, Mambriani A, Barbi E, Girelli R, Giardino A, Frigerio I, Scalapogno R, Avitabile A, Castellani S, Milella M, Butturini G. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. *Pancreatol.* 2021 Apr 19;S1424-3903(21)00143-5.
95. Pietrobono S, and **Melisi D**. A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. *Cell Mol Gastroenterol Hepatol.* 2021 Jun 25:S2352-345X(21)00120-X.
96. Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, **Melisi D**, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. *Oncol Ther.* 2021 Jul 10.
97. Sabbadini F, Bertolini M, De Matteis S, Mangiameli D, Contarelli S, Pietrobono S, Melisi D. The Multifaceted Role of TGF- β in Gastrointestinal Tumors. *Cancers (Basel).* 2021 Aug 5;13(16):3960.
98. Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, and **Melisi D**. First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. *Clin Cancer Res.* 2021 Sep 21:clincanres.1504.2021. doi: 10.1158/1078-0432.CCR-21-1504.
99. Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, **Melisi D**, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. *Expert Rev Gastroenterol Hepatol.* 2021
100. Gaule M, Pesoni C, Quinzii A, Zecchetto C, Casalino S, Merz V, Contarelli S, Pietrobono S, Vissio E, Molinaro L, Manzin E, Volpatto R, Vellani G, and **Melisi D**. Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion. *JCO Precis Oncol.* 2022 Jan;6:e2100400. doi: 10.1200/PO.21.00400.
101. Caputo F, Gelsomino F, Spallanzani A, Pettorelli E, Benatti S, Ghidini M, Grizzi G, Ratti M, Merz V, Messina C, Tonelli R, Luppi G, **Melisi D**, Dominici M, Salati M. Multicentre match-paired analysis of advanced biliary cancer long-term survivors: the BILONG study. *Clin Res Hepatol Gastroenterol.* 2022 May 21:101955.
102. Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, **Melisi D**. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. *Front Surg.* 2022 May 4;9:866173.
103. Normanno N, Martinelli E, **Melisi D**, Pinto C, Rimassa L, Santini D, Scarpa A. Role of molecular genetics in the clinical management of cholangiocarcinoma. *ESMO Open.* 2022 Jun;7(3):100505.
104. Quinzii A, Zecchetto C, Casalino S, Gaule M, Pesoni C, Merz V, Contarelli S, Pietrobono S, Benhadji KA, **Melisi D**. Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports. *Clin Drug Investig.* 2022 Aug;42(8):697-701.
105. Pietrobono S, De Paolo R, Mangiameli D, Marranci A, Battisti I, Franchin C, Arrigoni G, **Melisi D**, Polisenio L, Stecca B. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells. *J Biol Chem.* 2022 Sep;298(9):102353.
106. Rizzo A, Salati M, Frega G, Merz V, Caputo F, Di Federico A, Palloni A, Carloni R, Ricci AD, Gadaleta-Caldarola G, Messina C, Spallanzani A, Gelsomino F, Benatti S, Luppi G, **Melisi D**, Dominici M, Brandi G. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. *Medicina (Kaunas).* 2022 Oct 27;58(11):1543.
107. Zecchetto C, Quinzii A, Casalino S, Gaule M, Pesoni C, Merz V, Pietrobono S, Mangiameli D, Pasquato M, Milleri S, Giacomuzzi S, Bencivenga M, Tomezzoli A, de Manzoni G, **Melisi D**. Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. *J Pers Med.* 2023 Mar 11;13(3):508.
108. Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino

- S, Bergamo F, De Toni C, **Melisi D**, Lonardi S. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. *Cancer Med*. 2023 Jul;12(13):14337-14345. doi: 10.1002/cam4.6111.
109. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, **Melisi D**, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. *Lancet*. 2023 Jul 24:S0140-6736(23)00961-3.
 110. Wainberg ZA, **Melisi D**, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghoul F, O'Reilly EM. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. *Lancet* 2023 Sep 11;S0140-6736(23)01366-1. doi: 10.1016/S0140-6736(23)01366-1. Online ahead of print.
 111. Pietrobono S, Sabbadini F, Bertolini M, Mangiameli D, De Vita V, Fazzini F, Lunardi G, Casalino S, Scarlato E, Merz V, Zecchetto C, Quinzii A, Di Conza G, Lahn M, **Melisi D**. Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma. *Cancer Res*. 2023 Sep 22. doi: 10.1158/0008-5472.CAN-23-0104. Online ahead of print.
 112. Bencivenga M, Torroni L, Dal Cero M, Quinzii A, Zecchetto C, Merz V, Casalino S, Taus F, Pietrobono S, Mangiameli D, Filippini F, Alloggio M, Castelli C, Iglesias M, Pera M, **Melisi D**. YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer. *J Pers Med*. 2023 Aug 24;13(9):1294. doi: 10.3390/jpm13091294.
 113. Rimassa L, Brandi G, Niger M, Normanno N, **Melisi D**; Delphi Panel Members. Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement. *Crit Rev Oncol Hematol*. 2023 Dec;192:104146. doi: 10.1016/j.critrevonc.2023.104146. Epub 2023 Sep 28.
 114. **Melisi D**, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbriellini A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nTRO trial. *Eur J Cancer*. 2024 Jan;196:113430. doi: 10.1016/j.ejca.2023.113430. Epub 2023 Nov 11.
 115. Augustinus S, van Laarhoven HWM, Cirkel GA, de Groot JWB, Groot Koerkamp B, Macarulla T, **Melisi D**, O'Reilly EM, van Santvoort HC, Mackay TM, Besselink MG, Wilmink JW; Dutch Pancreatic Cancer Group. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study. *Cancers (Basel)*. 2023 Nov 27;15(23):5603. doi: 10.3390/cancers15235603.
 116. Merz V, Messina C, Zecchetto C, Quinzii A, Frisinghelli M, Trentin C, Salati M, Caffo O, **Melisi D**. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials. *Clin Oncol (R Coll Radiol)*. 2024 Feb;36(2):87-97. doi: 10.1016/j.clon.2023.12.005. Epub 2023 Dec 15.
 117. Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, **Melisi D**, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamperi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. A phase II/III randomized clinical trial of CisPlatin pLUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patients with resectable Biliary Tract Cancers (BTC) at high risk for recurrence: PURITY study. *BMC Cancer*. 2024 Apr 8;24(1):436.
 118. Melisi D, Casalino S, Pietrobono S, Quinzii A, Zecchetto C, Merz V. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. *Ther Adv Med Oncol*. 2024 Apr 4;16:17588359241234487. doi: 10.1177/17588359241234487. eCollection 2024.
 119. Vogel A, Sahai V, Hollebecque A, Vaccaro GM, **Melisi D**, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK. An

open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024 Jun;9(6):103488. Vogel A, Sahai V, Hollebecque A, Vaccaro GM, **Melisi D**, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024 Jun;9(6):103488.

120. Giordano G, Milella M, Landriscina M, Bergamo F, Tirino G, Santaniello A, Zaniboni A, Vasile E, De Vita F, Re GL, Vaccaro V, Giommoni E, Natale D, Conca R, Santini D, Maiorino L, Sanna G, Ricci V, Iop A, Montesarchio V, Procaccio L, Noventa S, Bianco R, Febbraro A, Lonardi S, Tortora G, Sperduti I, **Melisi D**. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Cancer Med. 2024 Jun;13(12):e7345.
121. Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, Donohoe C, Eveno C, Gisbertz S, Grimminger P, Gockel I, Grabsch H, Kassab P, Langer R, Lonardi S, Maltoni M, Markar S, Moehler M, Marrelli D, Mazzei MA, **Melisi D**, Milandri C, Moenig PS, Mostert B, Mura G, Polkowski W, Reynolds J, Saragoni L, Van Berge Henegouwen MI, Van Hillegersberg R, Vieth M, Verlato G, Torroni L, Wijnhoven B, Tiberio GAM, Yang HK, Roviello F, de Manzoni G; Bertinoro Workshop Working Group. International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022. Gastric Cancer. 2024 Jul;27(4):649-671.
122. Merz V, Maines F, Marcucci S, Sartori C, Frisinghelli M, Trentin C, Kadrija D, Carbone FG, Michielan A, Gabbriellini A, **Melisi D**, Barbareschi M, Brolese A, Caffo O. Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma. J Cancer Res Clin Oncol. 2024 Jul 11;150(7):347.
123. Casalino S, Zecchetto C, Merz V, Quinzii A, Pietrobono S, **Melisi D**. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Ann Oncol. 2024 Sep;35(9):760-761.
124. Pietrobono S, Bertolini M, De Vita V, Sabbadini F, Fazzini F, Frusteri C, Scarlato E, Mangiameli D, Quinzii A, Casalino S, Zecchetto C, Merz V, **Melisi D**. CCL3 predicts exceptional response to TGFbeta inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. NPJ Precis Oncol. 2024 Oct 30;8(1):246.
125. Biesma NC, Graus MUJE, Cirkel GA, Besselink MG, de Groot JWB, Koerkamp BG, Herbschleb KH, Los M, Verdonk RC, Wilmink JW, Cervantes A, Valle JW, Valkenburg-van Iersel LBJ, Froeling FEM, Molenaar IQ, Daamen LA, de Vos-Geelen J, van Santvoort HC; Dutch Pancreatic Cancer Group. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Eur J Surg Oncol. 2024 Dec 12;51(3):109544.
126. Wainberg ZA, **Melisi D**, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Jin Leei W, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghoul F, O'Reilly EM. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Future Oncol. 2025 Feb 12:1-10.

I hereby authorize the treatment of my data according to the applicable local regulation about data protection and any further amendments

Verona, August 6th, 2025



Prof. Davide Melisi, MD, PhD